Article

Multispot laser system receives FDA clearance

The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA. It is intended to deliver a cost-effective solution to ophthalmologists dealing with epidemic levels of diabetic eye disease.

 

Clermont-Ferrand, France-The Vitra Multispot laser (Quantel Medical) has received a 510(k) market clearance from the FDA.  The product was developed by Quantel Medical to give access to advanced pattern-scanning technology to ophthalmology practices worldwide though intelligent design.

The laser combines advanced pattern scanning and solid-state green laser technologies in a compact portable platform to deliver a cost-effective solution to ophthalmologists around the world dealing with epidemic levels of diabetic eye disease in their patient populations, according to the company.

“The [multispot laser] has accelerated our capability to manage the growing number of diabetic patients coming to our practice for care and [has] improved our reputation for superior patient care since the pattern-scanning laser treatment . . . is less painful compared [with] the previous treatments many patients received with a conventional laser,” said Rama D. Jager, MD, MBA, FACS of University Retina, Oak Forest, IL, who was the first user of the Vitra Multispot in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.